ReviewAging medicine (Milton (N.S.W))2019
Advances in screening instruments for Alzheimer's disease.
Review in Aging medicine (Milton (N.S.W)), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Unmasking preclinical Alzheimer's pathology: auditory distraction cost and occupational reserve jointly discriminate amyloid positivity in subjective cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Mobile Health Interventions to Support Patients With Dementia During the COVID-19 Pandemic: A Systematic Review.Health science reports · 2026Review
- A brief checklist of modifiable dementia risk factors (RF12): associations with cognitive and affective measures in an Italian cohort.Frontiers in aging neuroscience · 2026Article
- Electrochemical Detection of Aβ42 and Aβ40 at Attomolar Scale via Optimised Antibody Loading on Pyr-NHS-Functionalised 3D Graphene Foam Electrodes.Biosensors · 2025Article
- Associations Between Prostate Cancer and Dementia: A Nationwide Study in Sweden.European urology oncology · 2025Article
- Predicting brain amyloid load with digital and blood-based biomarkers.Alzheimer's research & therapy · 2025Article
- Toward digitally screening and profiling AD: A GAMLSS approach of MemTrax in China.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Deep Learning of Speech Data for Early Detection of Alzheimer's Disease in the Elderly.Bioengineering (Basel, Switzerland) · 2023Article
- Article
- Exosomes Derived from Human Amniotic Fluid Mesenchymal Stem Cells Preserve Microglia and Neuron Cells from Aβ.International journal of molecular sciences · 2022Article
- Correctness and response time distributions in the MemTrax continuous recognition task: Analysis of strategies and a reverse-exponential model.Frontiers in aging neuroscience · 2022Article
- Scoping review: the empowerment of Alzheimer's Disease caregivers with mHealth applications.NPJ digital medicine · 2021Article
- A delicate balance: Psychotropic polypharmacy and anti-cholinergic use are correlated with fall incidence in Australian inpatients with dementia.Aging medicine (Milton (N.S.W)) · 2021Article
- A Critical Review of the Study of Neuroprotective Diets to Reduce Cognitive Decline.Nutrients · 2021Review
- A Brief Digital Cognitive Assessment for Detection of Cognitive Impairment in Cuban Older Adults.Journal of Alzheimer's disease : JAD · 2021Article
- Glucagon-like peptide-1 analog improves neuronal and behavioral impairment and promotes neuroprotection in a rat model of aluminum-induced dementia.Physiological reports · 2021Article
- Role of Mesenchymal Stem Cells in Counteracting Oxidative Stress-Related Neurodegeneration.International journal of molecular sciences · 2020Review
- Utility of MemTrax and Machine Learning Modeling in Classification of Mild Cognitive Impairment.Journal of Alzheimer's disease : JAD · 2020Article
- Advances in screening instruments for Alzheimer's disease.Aging medicine (Milton (N.S.W)) · 2019Review
- Outcome measurement instruments in neurodegenerative diseases: Comprehensive analysis and platform construction.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At its fundamental basis, Alzheimer's disease (AD) is a pathological process that affects neuroplasticity, leading to a specific disruption of episodic memory. This review will provide a rationale for calls to screen for the early detection of AD, appraise the currently available cognitive instruments for AD detection, and focus on the development of the MemTrax test, which provides a new approach to detect the early manifestations and progression of the dementia associated with AD. MemTrax assesses metrics that reflect the effects of neuroplastic processes on learning, memory, and cognition, which are affected by age and AD, particularly episodic memory functions, which cannot presently be measured with enough precision for meaningful use. Further development of MemTrax would be of great value to the early detection of AD and would provide support for the testing of early interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.